Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses resistance to CYP17 and AR inhibitors such as the AR-7 Splice Variant in prostate cancer at ASCO GU 2016 in San Francisco.
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses resistance to CYP17 and AR inhibitors such as the AR-7 Splice Variant in prostate cancer at ASCO GU 2016 in San Francisco.